Supriya Lifescience Reports Strong FY26 Performance with Q4 Revenue Growth of 50% Year-over-Year

Supriya Lifescience Reports Strong FY26 Performance with Q4 Revenue Growth of 50% Year-over-Year​

Supriya Lifescience Limited, a cGMP-compliant manufacturer specializing in Active Pharmaceutical Ingredients (APIs), has released its audited financial results for the quarter and year ended March 31, 2026. The company, which operates in more than 120 countries, reported significant year-over-year growth across its key segments, driven by strong demand in therapeutic areas such as antihistamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.

The company’s financial performance showed robust increases both in the fourth quarter and for the full fiscal year 2026.

Key Consolidated Financial Highlights​

The financial data for the quarter and the full year provides a clear picture of the company's growth trajectory.

Consolidated Financial Results (in Rs Cr)


\*Note: Q4 FY25 and Q4 FY26 data are presented here in the relevant rows for comparison.

The quarterly revenue in Q4 FY26 saw a 50.2% year-over-year surge, reaching Rs 276.53 crore compared to Rs 184.11 crore in Q4 FY25. Similarly, EBITDA for the quarter stood at Rs 97.62 crore, down slightly from Rs 67.58 crore in Q4 FY25, although the EBITDA margin was 35.3% versus 36.7% in the previous year. Profit After Tax (PAT) for Q4 FY26 was reported at Rs 74.23 crore, up from Rs 50.37 crore in Q4 FY25.

For the full fiscal year, revenue from operations grew by 18.9% year-over-year to Rs 827.87 crore, up from Rs 696.48 crore in FY25. EBITDA for FY26 reached Rs 294.05 crore, representing a 12.8% year-over-year growth from Rs 260.79 crore in FY25. PAT increased by 11.3% year-over-year, posting Rs 209.12 crore compared to Rs 187.96 crore in FY25.

Operational and Market Highlights​

The anesthetic segment served as the primary growth engine throughout FY26, contributing 54% of total revenues, an increase from 49% in FY25. The vitamins segment also showed enhanced traction, increasing its revenue contribution to 12% from 11% during the same period.

Geographically, Europe remained the largest market for the company, contributing 40% of FY26 revenues and 44% of Q4 FY26 revenues. Asia contributed 33% of FY26 revenues and 34% of Q4 FY26 revenues, while LATAM contributed 20% of FY26 revenues and 17% in Q4 FY26. The export contribution remained strong, accounting for approximately 82% of total revenues in FY26.

Operationally, the company’s capacity utilization improved to 74% in FY26 from 70% in FY25. This improvement was supported by the ramp-up of Module E at the Lote facility and consistent operational efficiencies.

The company commercialized its Liquid Anesthetic product during the year and experienced promising traction in newly launched products within the cardiovascular and ADHD segments. Furthermore, the Ambernath formulation facility commissioned five finished dosage manufacturing lines and continued its progress on validation and dossier submission activities across several regulated markets.

Dr. Satish Wagh, Executive Chairman and Whole Time Director, commented on the strong performance, stating that the results reflect steady demand across key therapeutic segments and healthy traction in regulated markets. He noted that the combination of improved capacity utilization, global market expansion, and contributions from new products supported the growth throughout the year.

SUPRIYA Stock Price Movement​

On Wednesday, Supriya Lifescience Limited shares gained momentum, rallying 3.85% to close at ₹807.25. The stock experienced robust trading on the day, recording a significant volume of 532,518 shares.